13
June
2022

ADQ to acquire leading Turkish pharmaceuticals company Birgi Mefar Group

Highlights

  • ADQ to acquire leading Turkish Pharmaceutical Contract Development and Manufacturing Organization (CDMO) of sterile solutions and injectables
  • Investment expands ADQ’s life sciences capabilities in sterile injectables and wider pharmaceutical services segments, while complementing its broader commitment to Turkey

ADQ, an Abu Dhabi-based investment and holding company, today announced it has entered into a definitive agreement to acquire Birgi Mefar Group (BMG), one of Turkey’s leading producers of sterile injectable products.

As a full-service pharmaceutical CDMO, BMG is a production service provider for sterile injectable products, namely vials and pre-filled syringes used for vaccines. BMG also produces primary packaging ampoules and vials for other sterile injectables and specializes in the growing demand for drug lyophilization. The company exports to more than 30 countries, including markets across Europe and Asia with more than 50 years of expertise and excellence.

"BMG's diversified offering and manufacturing capabilities make the company a strategic addition to our growing portfolio as we continue to shape the UAE’s healthcare & life sciences platform. Turkey is an important market for our investments, and BMG brings with it a strong presence throughout the pharmaceutical supply chain."

Fahad Al Qassim, Executive Director, Healthcare & Life Sciences Portfolio at ADQ

"Joining ADQ’s portfolio is an exciting next step in our journey that will elevate our offering and enable us to scale in lucrative markets like the UAE and wider MENA region."

Faik Somer, CEO at Birgi Mefar Group

This comes as part of ADQ’s efforts to build a fully integrated healthcare and life sciences platform in the UAE. It will provide ADQ exposure to a fast-growing market of injectables and high-value treatments, such as vaccines as well as access a wide customer network ranging from large multinationals to local and regional players. Moreover, the acquisition will enable BMG to join ADQ’s Healthcare and Life Science portfolio that aims to enhance manufacturing, distribution and commercialization capabilities, including the provision of sterile health products and injectable solutions.

Earlier this year, ADQ acquired Acino, a Swiss-based pharmaceutical manufacturer with presence in more than 90 countries. In 2021, ADQ acquired Pharmax, a leading pharmaceutical manufacturer in the UAE, and Amoun, one of Egypt’s leading pharmaceutical companies. ADQ also retains a minority stake in Biocon Biologics Limited, India’s largest biopharmaceutical company.

The transaction is subject to customary closing conditions, including regulatory approvals.

About ADQ

Established in 2018, ADQ is an Abu Dhabi-based investment and holding company with a broad portfolio of major enterprises. Its investments span key sectors of the UAE’s diversified economy including energy and utilities, food and agriculture, healthcare and life sciences, and mobility and logistics, amongst others. As a strategic partner of Abu Dhabi’s government, ADQ is committed to accelerating the transformation of the Emirate into a globally competitive and knowledge-based economy.

For more information, visit adq.ae or write to media@adq.ae. You can also follow ADQ on X, Instagram and LinkedIn.

Direct to your inbox

ADQ News and Insights delivered directly to your inbox

Latest News

The ADQ FWD platform brings together industry experts, government, and advocacy leaders to discuss and address issues of economic and strategic importance for the UAE.